Stocks · News reference
FibroBiologics Regains Nasdaq Compliance
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FibroBiologics Secures US Patent For Therapeutic Use Of Fibroblasts For Use In Wound Healing
Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of WoundsHOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc.
FibroBiologics Receives Patent From United States Patent And Trademark Office Titled 'Treatment Of Disc Degenerative Disease And Stimulation Of Proteoglycan Synthesis By Fibroblast Conditioned Media And Formulations Thereof'
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and
FibroBiologics Releases Third cGMP CYWC628 Drug Product Batch For Shipment To Australia, Supporting Ongoing Phase 1/2 Diabetic Foot Ulcer Trial
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and